DEVELOPMENT AND CLINICAL MANUFACTURE AGREEMENTDevelopment and Clinical Manufacture Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
This Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of 30 April 2012 (the “Effective Date”) by and between METABOLEX, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“METABOLEX”) and SIEGFRIED AG, a Swiss Company, with its principal address place of business located at Untere Brühlstrasse 4, Zofingen CH4800 Switzerland (“SIEGFRIED”). METABOLEX and SIEGFRIED may be referred to herein individually as a “Party” or collectively as the “Parties”.
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • California
THIS LICENSE AND DEVELOPMENT AGREEMENT is made and entered into as of June 30, 1998 (the “Effective Date”) by and between METABOLEX, INC., a Delaware corporation with a place of business at 3876 Bay Center Place, Hayward, CA 94545 (“Metabolex”), and DIATEX, INC., a Texas corporation with a place of business at 105 Elm Spring Lane, San Antonio, TX 78231 (“DiaTex”). Metabolex and DiaTex may be referred to herein as a “Party” or, collectively, as “Parties.”
DEVELOPMENT AND CLINICAL MANUFACTURE AGREEMENTDevelopment and Clinical Manufacture Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
This Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of June 5, 2012 (the “Effective Date”) by and between Metabolex, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”) and Patheon Inc., a Canadian company with its principal place of business located at 2100 Syntex Court, Mississauga, Ontario, L5N 7K9, Canada (“Patheon”). Metabolex and Patheon may be referred to herein individually as a “Party” or collectively as the “Parties”.
METRICS, INC. STANDARD DEVELOPMENT AGREEMENTStandard Development Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT, effective as of October 31, 2006, by and between Metrics, Inc., a North Carolina corporation, having a principal place of business at 1240 Sugg Parkway, Greenville, NC 27834 (“METRICS”), and Metabolex, Inc., a Delaware corporation, having a principal place of business at 3876 Bay Center Place, Hayward, CA 94545 (“COMPANY”).
FIRST AMENDMENTLicense and Development Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “First Amendment”), dated April 15, 1999, (“Effective Date of this First Amendment”) entered by and between Metabolex, Inc., a Delaware corporation with a place of business at 3876 Bay Center Place, Hayward, CA 94545 (“Metabolex”), and DiaTex, Inc., a Texas corporation with a place of business at 105 Elm Spring Lane, San Antonio, TX 78231 (“DiaTex”) amends the License and Development Agreement by and between the same Parties, dated June 30, 1998 (the “Agreement”). Metabolex and DiaTex may be referred to herein as a “Party” or, collectively, as “Parties.”
